Loading clinical trials...
Loading clinical trials...
Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder
Conditions
Interventions
gabapentin enacarbil
Placebo
Locations
10
United States
University of California Los Angeles
Los Angeles, California, United States
Friends Research Institute
San Francisco, California, United States
University of Miami, Miller School of Medicine
Miami, Florida, United States
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Boston University Medical Center
Boston, Massachusetts, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Start Date
June 1, 2015
Primary Completion Date
March 1, 2017
Completion Date
March 1, 2017
Last Updated
November 14, 2018
NCT05855668
NCT07071779
NCT07413458
NCT06793488
NCT06939088
NCT06648642
Lead Sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions